175 related articles for article (PubMed ID: 12927446)
1. Do we need more iron-chelating drugs?
Kontoghiorghes GJ
Lancet; 2003 Aug; 362(9382):495-6. PubMed ID: 12927446
[No Abstract] [Full Text] [Related]
2. Current status of iron overload and chelation with deferasirox.
Choudhry VP; Naithani R
Indian J Pediatr; 2007 Aug; 74(8):759-64. PubMed ID: 17785900
[TBL] [Abstract][Full Text] [Related]
3. Iron mobilization using chelation and phlebotomy.
Flaten TP; Aaseth J; Andersen O; Kontoghiorghes GJ
J Trace Elem Med Biol; 2012 Jun; 26(2-3):127-30. PubMed ID: 22565013
[TBL] [Abstract][Full Text] [Related]
4. Treating iron overload: the state of the art.
Hershko C
Semin Hematol; 2005 Apr; 42(2 Suppl 1):S2-4. PubMed ID: 15846582
[No Abstract] [Full Text] [Related]
5. Recent developments in iron chelation therapy.
Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E
Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Kontoghiorghe CN; Kontoghiorghes GJ
Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
[TBL] [Abstract][Full Text] [Related]
7. The oral chelator deferasirox--a new perspective for patients with iron overload.
Fischer R
Haematologica; 2006 Jul; 91(7):865A. PubMed ID: 16818263
[No Abstract] [Full Text] [Related]
8. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
[No Abstract] [Full Text] [Related]
9. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.
Hershko C; Konijn AM; Nick HP; Breuer W; Cabantchik ZI; Link G
Blood; 2001 Feb; 97(4):1115-22. PubMed ID: 11159545
[TBL] [Abstract][Full Text] [Related]
10. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
Fischer R; Piga A; Harmatz P; Nielsen P
Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683
[TBL] [Abstract][Full Text] [Related]
11. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):329-47. PubMed ID: 16798657
[TBL] [Abstract][Full Text] [Related]
12. Long term deferiprone chelation therapy.
Hoffbrand VA; Wonke B
Adv Exp Med Biol; 2002; 509():127-39. PubMed ID: 12572992
[No Abstract] [Full Text] [Related]
13. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Balocco M; Carrara P; Pinto V; Forni GL
Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
[No Abstract] [Full Text] [Related]
14. Monitoring and treatment of iron overload: state of the art and new approaches.
Porter JB
Semin Hematol; 2005 Apr; 42(2 Suppl 1):S14-8. PubMed ID: 15846580
[No Abstract] [Full Text] [Related]
15. Deferasirox: pharmacokinetics and clinical experience.
Galanello R; Campus S; Origa R
Expert Opin Drug Metab Toxicol; 2012 Jan; 8(1):123-34. PubMed ID: 22176640
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
Vichinsky E; Torres M; Minniti CP; Barrette S; Habr D; Zhang Y; Files B;
Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212
[TBL] [Abstract][Full Text] [Related]
17. Iron chelation therapy for patients with sickle cell disease and iron overload.
Inati A; Khoriaty E; Musallam KM; Taher AT
Am J Hematol; 2010 Oct; 85(10):782-6. PubMed ID: 20721892
[No Abstract] [Full Text] [Related]
18. Bad liver and a broken heart.
Coates TD
Blood; 2014 Mar; 123(10):1434-6. PubMed ID: 24627546
[TBL] [Abstract][Full Text] [Related]
19. Iron chelators in myelodysplastic syndrome: to lower ferritin levels or to improve survival?
de Witte T
Leuk Res; 2013 Dec; 37(12):1605. PubMed ID: 24183304
[No Abstract] [Full Text] [Related]
20. Iron chelators for thalassaemia.
Hershko C; Konijn AM; Link G
Br J Haematol; 1998 Jun; 101(3):399-406. PubMed ID: 9633877
[No Abstract] [Full Text] [Related]
[Next] [New Search]
